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OBJECTIVE: To evaluate the association between chronic
illness with complexity (CIC) and optimal glycemic control.
PARTICIPANTS: Cross-sectional and longitudinal
analyses of Diabetes Epidemiologic Cohort database
of Veterans Health Administration (VHA) users with
diabetes, less than 75 years old, with HbA1c tests in
fiscal year (FY) 1999 and 2000, alive at FY2000 end
(N=95,423).
DESIGN/MEASUREMENTS: OutcomeswereHbA1c<7%
in each FY. CIC included three domains: nondiabetes
physical illness, diabetes-related, and mental illness/
substance abuse conditions. Other independent variables
included age, gender, race, marital status, VHA priority
status, and diabetes severity. Longitudinal analyses were
restricted to patients with HbA1c ≥ 7% in FY1999 and
included hospitalizations between final HbA1c’si n
FY1999 and FY2000. Multiple logistic regressions exam-
ined associations between CIC categories and HbA1c.
RESULTS: In FY1999, 33% had HbA1c <7%. In multi-
variate analyses, patients with nondiabetes physical
illness and mental illness/substance abuse were more
likely to have HbA1c <7% in FY1999 [adjusted odds
ratios for cancer (AOR), 1.31; 95% CI (1.25–1.37);
mental illness only, 1.18; 95% CI (1.14–1.22)]. Those
with diabetes-related complications were less likely to
have HbA1c <7% in FY1999. Associations generally
held in FY2000. However, conditions in the mental
illness/substance abuse complexity domain were less
strongly associated with HbA1c <7%. Macrovascular-
related hospitalizations were positively associated with
HbA1c <7% [AOR, 1.41; 95% CI (1.34–1.49)].
CONCLUSIONS: The association between CIC and
HbA1c <7% isheterogeneous and depends onthe domain
of complexity. The varying associations of CIC categories
with optimal glycemic control suggest the need for
appropriate risk adjustment when using HbA1c <7% as
a valid performance measure for diabetes quality of care.
KEY WORDS: diabetes; veterans; performance measurement;
glycemic control; chronic illness with complexity.
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INTRODUCTION
Controlling glycemia is critical to reducing the risk of costly
and disabling complications associated with both type 1 and
type 2 diabetes.
1,2 A measure of “poor glycemic control,”
defined as glycosylated hemoglobin A1c (HbA1c) level greater
than 9.0%, is recommended as a performance measure
because it represents “poor control” for all patients, including
those with chronic illnesses with complexity (CIC).
3–6 “Optimal
glycemic control,” HbA1c target values of less than 7%, has
been used to guide quality improvement efforts only within
plans and practices because differences in patient case mix,
including prevalence of CIC among plans, cannot be adequate-
ly addressed by current case mix adjustment methods.
Recently, however, HbA1c <7% for all persons 18–75 years
old, without any appropriate risk adjustment or exclusion
criteria, was adopted for public reporting of health plans.
4
Studies have examined the association between chronic
comorbid conditions and glycemic control. The most common
adjustment for physical comorbidity has been the Charlson
Comorbidity Index.
7–11 Other measures include presence of
diabetes-related complications
11–13 and simple count of
comorbid conditions.
14 However, these measures may not
adequately control for CIC that may influence glycemic control.
Summary scores like the Charlson Comorbidity Index do not
provide insight into comorbidities that may have varying
associations with glycemic control. Therefore, the current
paper uses an alternative and comprehensive classification of
CIC based on theory and prior empirical research.
In the absence of a widely accepted conceptual framework
for CIC, we used the recent conceptual model of comorbid
chronic illness complexity in diabetes care by Piette and Kerr
15
as a starting point and operationalized CIC in the context of
glycemic control. Our categories of CIC were designed to reflect
overall similarity in pathophysiologic profiles, treatment plans,
and self-management strategies in achieving glycemic control
and the need to develop a reasonable summarization of CIC.
We categorized CIC into three domains of complexity: (1)
nondiabetes-related physical illness, (2) diabetes-related, and
(3) mental illness and substance abuse conditions. Our
primary objective in this manuscript is to evaluate associa-
tions between CIC categories and HbA1c<7% in Veterans
Health Administration (VHA) clinic users with diabetes.
Macrovascular, microvascular complications, and metabolic
decompensation formed the domain diabetes-related complex-
ity because these tend to co-occur in patients with diabetes,
408increase cardiovascular morbidity, and treatment strategies
are synergistic with contemporary standards of diabetes
management. For example, macrovascular complications con-
sisted of angina, myocardial infarction, congestive heart
failure, arrhythmia, peripheral vascular disease, stroke, tran-
sient ischemic attack, and hypertension. For an individual
with diabetes and a macrovascular complication, the treat-
ment plans would continue to focus on intensive glycemic
control in addition to reducing the elevated risk of cardiovas-
cular complications.
Non-diabetes physical illness complexity domain included
categories of cancer, musculoskeletal, gastrointestinal, pulmo-
nary, and other diseases because of a lower degree of
synergism in treatment plans and self-management strategies
compared to the categories in the domain of diabetes-related
complexity. For example, if an individual has diabetes and a
musculoskeletal condition, the self-management of diabetes
(e.g., exercise) may be compromised. In addition, we developed
a hierarchy within this domain to reflect increasing complexity
with diabetes management. In the presence of clinically
dominant conditions (e.g., cancer), in the short-term, the focus
may revolve around managing and treating cancer rather than
diabetes. Similarly, if a person with diabetes had at least one
disease in all three categories (musculoskeletal, gastrointestinal,
pulmonary), addressing diabetes management becomes highly
complex. Because of empirical evidence that mental illness and
substance abuse conditions exert their own unique influence on
diabetes outcomes and care, we considered mental illness and
substance abuse in a separate domain of complexity.
16
In summary, our classification provides an alternative
specification for CIC based on overall similarities in patho-
physiologic profiles, treatment plans, and self-management
strategies that may influence glycemic control. The primary
objective of this paper is to analyze the association between
various categories of CIC based on our conceptualization and
optimal glycemic control in VHA users with diabetes.
METHODS
Data
Our data are from the Diabetes Epidemiologic Cohort (DepiC),
a dataset of merged nationwide VHA inpatient and outpatient
administrative files, pharmaceutical utilization, and laboratory
data (the VA Healthcare Analysis and Information Group: VA-
HAIG) and Medicare paid claims on nationwide veteran clinic
users identified with diabetes.
17 For the current paper, we
used the cohort identified with diabetes in fiscal year (FY) 1999
(prevalent and incident cases) and followed through FY2000.
Medicare claims are used because prior research has demon-
strated that using only VHA administrative data can underes-
timate the prevalence of chronic illness.
18 Thus, to determine
prevalence of CIC categories among veterans, we utilized a
merged dataset that included both VHA administrative and
Medicare claims data. Because Medicare claims data are not
available for Medicare Health Maintenance Organization
enrollees, they were excluded from the analytic dataset. The
laboratory values and pharmaceutical utilization (VA-HAIG)
data were based only on VHA files because Medicare claims
data have no laboratory values and Medicare did not cover
prescription drugs during the period of our study. We used
FY1999/2000 data because of their extensive validation
10,19
and nonavailability of DepiC dataset with merged Medicare
data beyond FY2000.
Study Population
The study population (N=95,423) consisted of VHA users
diagnosed with diabetes during FY1999, aged less than
75 years as per standard practice,
4 and alive at the end of
FY2000. We also required that individuals have HbA1c values
in both FY1999 and FY2000 with at least 90 days interval
between the final HbA1c in FY1999 and FY2000.
8
Measures
Dependent Variable: Glycemic Control. The dependent
variable of our analyses was glycemic control measured by
the last measurement of HbA1c in the FY. For our primary
analyses, we used HbA1c <7%. For our secondary analyses, we
used HbA1c <8%. Both these thresholds were used because
the definition of optimal glycemic control (HbA1c <7% or
HbA1c <8%) remains a controversial policy issue.
20
For our primary longitudinal analysis, we included only
those individuals with HbA1c ≥7% in FY1999 (N=64,156)
because of our focus on the association between CIC categories
and achieving optimal glycemic control given lack of optimal
glycemic control during the baseline year.
Key Independent Variables—Chronic Illness with Complexity.
Nondiabetes physical illness complexity. Nondiabetes physical
illness complexity was hierarchically evaluated using five
categories of chronic illness based on International Classification
ofDiseases,9threvision,ClinicalModification(ICD-9-CM)codes
21
(see Table 5 in Appendix A). The presence of cancer was
given priority, and we categorized gastrointestinal,
musculoskeletal, pulmonary, and other diagnoses only
among those without cancer. Thus, our final classification
of nondiabetes physical illness complexity consisted of seven
groups: (1) any cancer; (2) all three (gastrointestinal,
musculoskeletal, pulmonary diagnoses); (3) any two; (4)
only gastrointestinal; (5) only musculoskeletal; (6) only
pulmonary; and (7) none of these nondiabetes physical
illness categories.
Diabetes-related complexity. This was measured by the
presence of microvascular (diabetic retinopathy, renal disease,
ulcers, and lower extremity amputations), macrovascular
(coronary artery disease, congestive heart failure, arrhythmia,
cerebrovascular disease, and peripheral vascular disease),
22,23
and metabolic decompensation (uncontrolled and short-term
complications of diabetes) derived from ICD-9-CM codes.
24
Mental illness/substance abuse complexity. We used ICD-
9-CM codes of 295–314 (other than substance abuse codes)
to represent mental illness. Substance abuse consisted of drug
use, alcohol use, and tobacco use. Individuals were grouped
into four categories: (1) no substance abuse and no mental
illness; (2) substance abuse only; (3) mental illness only; and
(4) both mental illness and substance abuse.
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included age, gender, race/ethnicity, marital status, VHA
priority group status, dual VHA/Medicare use, endocrinology
care, and baseline severity of diabetes. Severity of diabetes was
based on the patient’s pharmaceutical treatment regimen (oral
agents only, insulin only, insulin and oral agents, no agents)
because the use of multiple oral agents or insulin is associ-
ated with increasing duration of the disease
25. Diabetes
medications, endocrinology care, and dual VHA/Medicare use
were all assessed in the 120 days before the HbA1c tests in
FY1999.
Longitudinal analysis included the presence of hospitaliza-
tion during the period between the two HbA1c tests because
hospitalization may interrupt normal management of diabetes
and may have an impact on HbA1c control. We followed a
similar taxonomy to our CIC categories, and based on
significant findings, we finally grouped them into three cate-
gories: (1) no hospitalization; (2) macrovascular-related hospi-
talization; and (3) other.
In our study population, individuals were tested for HbA1c
at different time points, which caused variation in time interval
between the last test in FY1999 and the last test in FY2000. We
adjusted for this varying number of months between the two
HbA1c tests by including it as a covariate in our regressions.
Statistical Techniques
Chi-square tests were used to assess unadjusted associations
between CIC categories and HbA1c <7%. Among all VHA users
with diabetes (N=95,423), we used logistic regressions to
investigate the effect of CIC on HbA1c in FY1999, controlling
for other independent variables. Parameter estimates from
logistic regressions were converted to odds ratios, and we also
report the 95% confidence intervals (CI). To understand how
CIC may influence longitudinal HbA1c outcomes, we evaluated
the association between CIC and HbA1c <7% in FY2000
among only those who had HbA1c ≥7% in FY1999 (N=64,156).
Sensitivity analysis. To ensure that the relationship was robust
across different HbA1c values, we tested the relationship
between CIC and HbA1c<8%, and these findings are
summarized in Table 4.
FINDINGS
The study population (N=95,423) was predominantly male
(98%), white (68%), married (61%), enrolled in Medicare (60%),
and younger than 65 years of age (59%; Table 1). A majority
were enrolled in the VHA through a priority status that
reflected having both no service connected disability and low
income (52%). Nearly one third (29%) had severe diabetes
based on the use of insulin in the 120 days before the HbA1c
test in FY1999. Only 3.3% saw an endocrinologist during that
period. In FY1999, 33% of patients had an HbA1c <7%, with
mean HbA1c value of 7.9 and standard deviation (SD) 1.8. In
FY2000, 37% of patients had HbA1c <7% with mean value of
7.8 (SD=1.8). Average time between HbA1c tests was approx-
imately 12 months.
Chronic Illness with Complexity
Nondiabetes Physical Illness Complexity. We found that 13%
had cancer, 0.8% had all three diagnoses (gastrointestinal,
pulmonary, and musculoskeletal), 8.5% had any two of
gastrointestinal, pulmonary, and musculoskeletal diagnoses,
3% had gastrointestinal diagnoses only, 6.6% had pulmonary
diagnoses only, and 23% had musculoskeletal diagnoses only.
Forty-five percent of the study population did not have any
cancer, gastrointestinal, musculoskeletal, or pulmonary
diagnoses.
Diabetes-Related Complexity. Forty-fourpercenthaddiagnoses
of macrovascular complications, 35% had microvascular
complications, and 31% were diagnosed with metabolic
decompensations. Twenty-nine percent had no microvascular
complications, macrovascular complications, or metabolic
decompensation.
Mental Illness/Substance Abuse Complexity. Mental illness
was diagnosed in 25% of the study population, either alone
(19%) or in combination with substance abuse (6%). Seven
percent of the study population had a substance abuse
diagnosis without mental illness.
Baseline Glycemic Control and Chronic Illness with Complexity.
In FY1999 (Table 2), overall, one third (N=31,267) had optimal
glycemic control (HbA1c <7%). Patients with nondiabetes
physical illness were more likely to have HbA1c <7% at
baseline than those without nondiabetes physical illness.
The percentages of VHA users with optimal control ranged
from 29% among those without nondiabetes physical illness
to 37% among patients with cancer and 39% among those
with all three gastrointestinal, musculoskeletal, and
pulmonary diagnoses. A similar pattern was seen in the
mental illness/substance abuse domain. Slightly more
patients with mental illness alone (35%) and both mental
illness and substance abuse (34%) had optimal glycemic
control compared to those without any mental illness or
substance abuse (32%).
On the other hand, we found that a lower proportion of
patients with diabetes-related conditions [macrovascular com-
plications (32%), microvascular complications (28%), and
metabolic decompensation (26%)] had HbA1c <7% compared
to those without these complications (33, 35, and 36%,
respectively).
Logistic regression on optimal glycemic control in FY1999
confirmed the bivariate findings (Table 2). Patients with any
cancer were more likely to have optimal glycemic control than
patients without nondiabetes physical illness [adjusted odds
ratio (AOR), 1.31; 95% CI (1.25–1.37)]. Similarly, individuals
who had gastrointestinal, pulmonary, or musculoskeletal
diagnoses, either individually or in combination, were more
likely to have optimal glycemic control than those without
nondiabetes physical illness. The AORs ranged from 1.12 to
1.56.
Those with mental illness only or both mental illness and
substance abuse were more likely to have optimal glycemic
control than their counterparts without any mental illness and
410 Meduru et al.: Chronic Illness with Complexity and Glycemic Control JGIMTable 1. Description of Study Population VHA Clinic Users with Diabetes FY 1999–2000
N Percent
All 95,423 100.0
Nondiabetes physical illness complexity
Any cancer 12,457 13.1
Gastrointestinal only (GI) 2,878 3.0
Pulmonary only (PU) 6,260 6.6
Musculoskeletal only (MS) 21,979 23.0
Any two (GI, PU, MS) 8,066 8.5
All three (GI, PU, MS) 795 0.8
No cancer, GI, PU, MS 42,988 45.1
Diabetes-related complexity
Macrovascular complications
Yes 42,376 44.4
No 53,047 55.6
Microvascular complications
Yes 33,012 34.6
No 62,411 65.4
Metabolic decompensation
Yes 29,735 31.2
No 65,688 68.8
Mental illness and substance abuse complexity
None 64,208 67.3
Only substance abuse 6,956 7.3
Only mental illness 18,431 19.3
Both 5,828 6.1
Medication use §
No oral hypoglycemics 18,403 19.3
Oral hypoglycemics only 49,215 51.6
Insulin only 17,207 18.0
Oral hypoglycemics and insulin 10,598 11.1
Gender
Women 2,024 2.1
Men 93,399 97.9
Race/Ethnicity
White 65,296 68.4
African American 16,437 17.2
Latino 3,513 3.7
Other 10,177 10.7
Age
<55 years 30,039 31.5
55–64 years 26,410 27.7
65–75 years 38,974 40.8
Marital status
Married 58,635 61.4
Other 36,788 38.6
Priority status FY1999
SC disability >30% 18,443 19.3
SC disability <20% 19,676 20.6
Non-SC, low income 49,634 52.0
Non-SC, high income 7,670 8.0
Medicare enrollment FY1999
Yes 57,167 59.9
No 38,256 40.1
Medicare enrollment FY 2000
Yes 57,532 60.3
No 37,891 39.7
Dual VHA/Medicare use §
VHA/Medicare 8,659 9.1
Single 48,508 50.8
No Medicare enrollment 38,256 40.1
Endocrinology visit §
Yes 3,129 3.3
No 92,294 96.7
HbA1c values 1999
Less than 7% 31,267 32.8
7–<8% 24,369 25.5
≥8% 39,787 41.7
HbA1c values 2000
Less than 7% 35,472 37.2
7–<8% 23,819 25.0
≥8% 36,132 37.9
Based on VHA clinic users with diabetes as of FY1999, aged under 75 years, enrolled in VHA or Medicare fee-for-service, and alive as of the end of
FY2000. The symbol “§” represents measurement of variables in the 120 days before the last HbA1c test in FY1999.
HbA1c Glycosylated hemoglobin, SC service-connected, FY fiscal year, VHA Veterans Health Administration, GI gastrointestinal diagnoses, PU pulmonary
diagnoses, MS musculoskeletal diagnoses
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[95% CI (1.14–1.22)].
Those with diabetes-related complications were less likely to
have HbA1c <7% than patients without diabetes-related
complications. The AORs ranged from 0.70 for metabolic
decompensation to 0.91 for macrovascular complications.
Longitudinal Optimal Glycemic Control and Chronic Illness with
Complexity. We also analyzed the relationship between CIC
and optimal glycemic control in FY2000 among those who did
not have optimal control in FY1999 (Table 3). Among those
who did not have optimal control in FY1999 (N=64,156), only
20% (N=13,056) achieved HbA1c <7% in FY2000. In
multivariate analysis, except for pulmonary diagnoses, those
with nondiabetes physical illness (range of AOR, 1.17–1.34)
were more likely to achieve optimal control than those without
(P<0.01 for all comparisons). Individuals with only mental
illness were slightly more likely to achieve optimal glycemic
control (P<0.01).
Patients hospitalized for macrovascular complications were
more likely to achieve optimal glycemic control [AOR, 1.41; 95%
CI (1.34–1.49)] compared to patients who were not hospitalized.
On the other hand, hospitalization for all other conditions was
not associated with achieving optimal glycemic control.
Sensitivity Analysis. Using HbA1c <8%, we found generally
similar direction and strength of associations between CIC and
glycemic control in FY1999 (Table 4). However, in the
longitudinal analyses, the associations between CIC and
HbA1c <8% were attenuated; only cancer and musculoskeletal
diagnoses were significantly associated with HbA1c <8% (P<
0.001). Within diabetes-related complexity, macrovascular and
microvascular conditions remained significantly and negatively
associated with HbA1c<8% (P<0.01). There was no significant
association between mental illness/substance abuse complexity
and HbA1c <8%.
DISCUSSION
Our findings demonstrate that the association between CIC
and optimal glycemic control varied by type of complexity. In
general, patients with nondiabetes physical or mental illness/
substance abuse complexities were more likely to have and
achieve HbA1c <7%. Patients with diabetes-related complica-
tions were less likely to have or achieve optimal glycemic
control.
There are many plausible explanations for the association
between nondiabetes physical illness complexity and achieving
HbA1c <7%. For example, nondiabetes physical illnesses may
result in improved HbA1c control due to pathophysiologic
mechanisms beyond the influence of the healthcare provider,
such as involuntary weight loss and anorexia that could result
in increased sensitivity to antiglycemic agents. In addition,
individuals with chronic diseases may have more contact with
the health care system and may be more likely to achieve
optimal glycemic control because of closer monitoring and
better care coordination. However, in our preliminary and
published research on diabetes quality of care measures,
controlling for frequency of visits did not alter the findings
regarding quality of care.
16,26 Further research is necessary to
understand the clinically relevant associations between non-
diabetes illness and glycemic control, their underlying
mechanisms, and implications for performance measurement.
VHA users with diabetes-related complexity were less likely
to be in control either at baseline or at follow-up. In other
studies, microvascular complications were associated with
both longer duration and poorer control of diabetes,
1,2 both
of which may increase the difficulty of achieving HbA1c <7%
even with newer insulin preparations.
27
We found that those with mental illness/substance abuse
complexity were more likely to have optimal glycemic control.
These findings are consistent with studies that suggest that
the association is dependent on the selection of the threshold
for glycemic control.
16 For example, Frayne et al.
16 reported
that when glycemic control was measured at HbA1c>7%, the
AOR for mental health conditions fell below 1.0, suggesting
better control.
A noteworthy finding of our study is that the associations
between CIC and glycemic control vary by HbA1c threshold. In
FY2000, both nondiabetes physical illness and mental illness/
substance abuse complexity were more strongly associated
with HbA1c <7% than HbA1c <8%. As noted in the concluding
paragraph, these findings have policy implications for perfor-
mance measurement of optimal glycemic control.
Hospitalization for macrovascular complications between
the baseline and follow-up HbA1c value was associated with
a greater likelihood of achieving HbA1c control relative to no
hospitalization, whereas hospitalization for all other conditions
was not associated with glycemic control. This finding may
reflect the clinically plausible overlap in treatments for acute
cardiovascular conditions and diabetes.
28
Strengths of the study include a nationwide population,
longitudinal study design, inclusion of ambulatory and inpa-
tient data, and incorporation of multiple disease categories to
define CIC. We also acknowledge some limitations of our study.
We were unable to explicitly measure the severity of diabetes or
other illnesses within disease categories. Because our study
population was relatively homogeneous, validation in other
populations using clinical data would enhance the generaliz-
ability of our findings. In addition, individuals with CIC may
have more interactions with the healthcare system and receive
better care. We could not test this hypothesis because our CIC
categories were defined using the ICD-9-CM codes recorded in
administrative data. It is likely that those with more visits have
more unique diseases coded and, therefore, are more likely to
be classified in CIC categories. Thus, the number of visits may
have had an influence on our CIC categorization itself.
Although our data are 6–7 years old and there has been a
decline in mean HbA1c levels during FY2000 through FY2003,
the proportion of individuals with HbA1c <7% did not change
(Pogach, personal communication). Thus, we believe that use
of more recent data may not lead to substantially different
conclusions.
The varying associations of CIC categories with optimal
glycemic control have implications for the validity of using
HbA1c <7% threshold as a performance measure for diabetes
quality of care. When using HbA1c <7% as a performance
measure, appropriate risk adjustment based on CIC may be
necessary. In the absence of validated and widely accepted risk
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With optimal glycemic control Logistic regression on optimal glycemic
control
N % AOR 95% CI
All 31,267 32.8
Nondiabetes physical illness complexity***
Any cancer 4,643 37.3 1.31 [1.25, 1.37]***
Gastrointestinal only (GI) 1,095 38.0 1.56 [1.43, 1.69]***
Pulmonary only (PU) 2,031 32.4 1.12 [1.05, 1.19]***
Musculoskeletal only (MS) 7,612 34.6 1.22 [1.17, 1.26]***
Any two (GI, PU, MS) 2,972 36.8 1.37 [1.30, 1.44]***
All three (GI, PU, MS) 306 38.5 1.44 [1.24, 1.67]***
No cancer, GI, PU, MS 12,608 29.3
Diabetes-related complexity
Macrovascular complications***
Yes 13,604 32.1 0.91 [0.89, 0.94]***
No 17,663 33.3
Microvascular complications***
Yes 9,278 28.1 0.85 [0.82, 0.87]***
No 21,989 35.2
Metabolic decompensation***
Yes 7,764 26.1 0.70 [0.68, 0.72]***
No 23,503 35.8
Mental illness and substance abuse complexity***
None 20,585 32.1
Only substance abuse 2,262 32.5 1.05 [0.99, 1.11]
Only mental illness 6,461 35.1 1.18 [1.14, 1.22]***
Both 1,959 33.6 1.15 [1.08, 1.22]***
Medication use §***
No oral hypoglycemics 9,164 49.8 1.85 [1.78, 1.91]***
Oral hypoglycemics only 16,799 34.1
Insulin Only 3,539 20.6 0.53 [0.51, 0.55]***
Oral hypoglycemics and insulin 1,765 16.7 0.41 [0.39, 0.44]***
Gender
Women 649 32.1 1.06 [0.96, 1.17]
Men 30,618 32.8
Race/Ethnicity***
White 22,392 34.3
African American 4,852 29.5 0.89 [0.85, 0.92]***
Latino 1,078 30.7 0.92 [0.85, 1.00]*
Other 2,945 28.9 0.89 [0.85, 0.94]***
Age***
<55 years 8,577 28.6
55–64 years 8,463 32.0 1.18 [1.14, 1.23]***
65–75 years 14,227 36.5 1.32 [1.26, 1.39]***
Marital status**
Married 19,434 33.1 0.99 [0.96, 1.02]
Other 11,833 32.2
Priority status FY1999***
SC disability>30% 6,253 33.9 1.06 [0.99, 1.12]
SC disability<20% 6,405 32.6 0.98 [0.92, 1.04]
Non-SC, low income 16,030 32.3
Non-SC, high income 2,579 33.6 0.96 [0.91, 1.01]
Dual VHA/Medicare use §***
VHA/Medicare 2,908 33.6 1.01 [0.96, 1.06]
Single 17,151 35.4
No Medicare enrollment 11,208 29.3 0.90 [0.86, 0.94]***
Endocrinology visit §***
Yes 887 28.3 1.03 [0.95, 1.12]
No 30,380 32.9
Percent with and predictors of optimal glycemic control. VHA clinic users with diabetes (N=95,423). Based on VHA clinic users with diabetes as of
FY1999, aged under 75 years, enrolled in VHA or Medicare fee-for-service and alive as of the end of FY2000. Optimal glycemic control defined as HbA1c
values less than 7%. Logistic regression includes intercept as well. The symbol “§” represents measurement of variables in the 120 days before the last
HbA1c test in FY1999. Asterisks represent group differences.
HbA1c Glycosylated hemoglobin, SC service-connected, FY fiscal year, VHA Veterans Health Administration, GI gastrointestinal diagnoses, PU pulmonary
diagnoses, MS musculoskeletal diagnoses, AOR adjusted odds ratio, CI confidence interval
*0.01eP<0.05
**0.001eP<0.01
***P<0.001
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20 our findings highlight the need for
developing appropriate risk adjustment models for optimal
glycemic control. An alternative approach may be to use
HbA1c <8% to measure optimal glycemic control, which is less
influenced by CIC categories. In addition, for performance
measurement, excluding individuals with clinically dominant
conditions such as cancer or who are in their last years of life
could be considered.
29 These approaches have been used in
performance measurement of other conditions,
30 are consis-
tent with guidelines,
31–33 and acknowledge the importance of
accounting for complexities in diabetes management in
patients with CIC rather than considering all patients equiv-
alent for the purpose of performance measurement. Further
research is needed to elucidate the mechanisms of these
associations to improve performance measurement of optimal
glycemic control.
Table 3. Optimal Glycemic Control in FY2000 by CIC among VHA Clinic Users with Diabetes and with Less Than Optimal Control in FY1999
With optimal glycemic control Logistic regression on optimal glycemic
control
N % Sig AOR 95% CI Sig
All 13,056 20.4
Nondiabetes physical illness complexity ***
Any cancer 1,884 24.1 1.24 [1.17, 1.32] ***
Gastrointestinal only (GI) 411 23.1 1.31 [1.17, 1.47] ***
Pulmonary only (PU) 875 20.7 1.08 [0.99, 1.17]
Musculoskeletal only (MS) 3,080 21.4 1.17 [1.12, 1.23] ***
Any two (GI, PU, MS) 1,163 22.8 1.20 [1.12, 1.30] ***
All three (GI, PU, MS) 127 26.0 1.34 [1.09, 1.65] **
No cancer, GI, PU, MS 5,516 18.2
Diabetes-related complexity
Macrovascular complications
Yes 5,954 20.7 0.90 [0.86, 0.94] ***
No 7,102 20.1
Microvascular complications ***
Yes 4,394 18.5 0.88 [0.84, 0.92] ***
No 8,662 21.4
Metabolic decompensation ***
Yes 4,266 19.4 0.96 [0.92, 1.00] *
No 8,790 20.8
Mental illness and substance abuse complexity *
None 8,736 20.0
Only substance abuse 998 21.3 1.08 [1.00, 1.17] *
Only mental illness 2,536 21.2 1.08 [1.02, 1.13] **
Both 786 20.3 1.02 [0.94, 1.12]
Medication use§ ***
No oral hypoglycemics 2,839 30.7 1.59 [1.51, 1.67] ***
Oral hypoglycemics only 6,956 21.5
Insulin only 2,004 14.7 0.63 [0.60, 0.67] ***
Oral hypoglycemics and insulin 1,257 14.2 0.61 [0.57, 0.65] ***
Gender
Women 252 18.3 0.96 [0.83, 1.10]
Men 12,804 20.4
Race/Ethnicity ***
White 9,187 21.4
African American 2,143 18.5 0.90 [0.85, 0.95] ***
Latino 458 18.8 0.95 [0.86, 1.06]
Other 1,268 17.5 0.93 [0.86, 1.00] *
Age ***
<55 years 3,590 16.7
55–64 years 3,684 20.5 1.29 [1.22, 1.36] ***
65–75 years 5,782 23.4 1.41 [1.32, 1.51] ***
Marital status
Married 7,990 20.4 0.96 [0.92, 1.00]
Other 5,066 20.3
Priority status FY1999
SC disability>30% 2,536 20.8 1.08 [1.00, 1.18]
SC disability<20% 2,677 20.2 1.05 [0.97, 1.15]
Non-SC, low income 6,817 20.3
Non-SC, high income 1,026 20.2 0.99 [0.92, 1.07]
Dual VHA/Medicare use§ ***
VHA/Medicare 1,309 22.8 1.04 [0.97, 1.12]
Single 6,937 22.1
No Medicare enrollment 4,810 17.8 0.94 [0.89, 1.00] *
(continued on next page)
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Logistic regression on optimal glycemic control
FY1999 (N=95,423) FY2000 (N=55,636, among those with ≥8%
in FY1999
AOR 95% CI Sig AOR 95% CI Sig
Nondiabetes physical illness complexity
Any cancer 1.35 [1.29, 1.41] *** 1.19 [1.11, 1.28] ***
Gastrointestinal only (GI) 1.42 [1.31, 1.54] *** 1.11 [0.98, 1.27]
Pulmonary only (PU) 1.11 [1.05, 1.17] *** 1.03 [0.95, 1.13]
Musculoskeletal only (MS) 1.26 [1.21, 1.30] *** 1.13 [1.07, 1.19] ***
Any two (GI, PU, MS) 1.36 [1.29, 1.43] *** 1.06 [0.97, 1.15]
All three (GI, PU, MS) 1.41 [1.21, 1.65] *** 1.36 [1.07, 1.74] *
No cancer, GI, PU, MS
Diabetes-related complexity
Macrovascular complications
Yes 0.95 [0.92, 0.98] *** 0.93 [0.89, 0.98] **
No
Microvascular complications
Yes 0.86 [0.83, 0.88] *** 0.85 [0.81, 0.89] ***
No
Metabolic decompensation
Yes 0.70 [0.68, 0.72] *** 1.03 [0.98, 1.07]
No
Mental illness and substance abuse complexity
None
Only substance abuse 1.03 [0.98, 1.09] 1.03 [0.95, 1.12]
Only mental illness 1.11 [1.07, 1.15] *** 1.03 [0.97, 1.09]
Both 1.10 [1.03, 1.16] ** 0.99 [0.90, 1.08]
Hospitalization between HbA1c tests
Macrovascular-related hospitalization NA 1.25 [1.18, 1.32] ***
Other hospitalization 1.00 [1.00, 1.01]
No hospitalization
Based on VHA clinic users with diabetes as of FY1999, aged under 75 years, enrolled in VHA or Medicare fee-for-service, and alive as of the end of
FY2000. FY2000 study population is restricted to those with HbA1c values ≥8% in FY1999. Optimal glycemic control defined as HbA1c values lower than
8%. Logistic regressions include intercepts as well. Other independent variables included in the regressions were: gender, race/ethnicity, age, marital
status, priority status, dual VHA/Medicare use, endocrinology visits, and medication use. Additionally, the regression on optimal glycemic control in
FY2000 included time and hospitalization between HbA1 tests as controls.
HbA1c Glycosylated hemoglobin, SC service-connected, FY fiscal year, VHA Veterans Health Administration, GI gastrointestinal diagnoses, PU pulmonary
diagnoses, MS musculoskeletal diagnoses, AOR, adjusted odds ratio, CI confidence interval
*0.01eP<0.05
**0.001eP<0.01
***P<0.001
Table 3. (continued)
With optimal glycemic control Logistic regression on optimal glycemic
control
N % Sig AOR 95% CI Sig
Endocrinology visit§ **
Yes 404 18.0 0.97 [0.86, 1.08]
No 12,652 20.4
Months between HbA1c tests
Mean 12.14 1.46 [1.36, 1.57] ***
Hospitalization between HbA1c tests ***
Macrovascular-related hospitalization 1,359 25.0 1.41 [1.34, 1.49] ***
Other hospitalization 2,513 24.8 1.00 [1.00, 1.01]
No hospitalization 9,184 18.9
Percent with and predictors of optimal glycemic control in FY2000 (N=64,156). Based on VHA clinic users with diabetes as of FY1999, aged under
75 years, enrolled in VHA or Medicare fee-for-service, and alive as of the end of FY2000 and having HbA1c values ≥7% in FY1999. Optimal glycemic
control defined as HbA1c values lower than 7%. Logistic regression includes intercept as well. The symbol “§” represents measurement of variables in the
120 days before the last HbA1c test in FY1999.
HbA1c Glycosylated hemoglobin, SC service-connected, FY fiscal year, VHA Veterans Health Administration, GI gastrointestinal diagnoses, PU pulmonary
diagnoses, MS musculoskeletal diagnoses, AOR adjusted odds ratio, CI confidence interval
*0.01eP<0.05
**0.001eP<0.01
***P<0.001
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Table 5. List of ICD-9-CM codes (CIC)
Category
Nondiabetes physical illness complexity
Cancers 140.xx, 141.xx, 142.xx, 143.xx, 144.xx, 145.xx, 146.xx,
147.xx, 148.xx, 149.xx, 150.xx, 151.xx, 152.xx, 153.xx,
154.xx, 155.xx, 156.xx, 157.xx, 158.xx, 159.xx, 160.xx,
161.xx, 162.xx, 163.xx, 164.xx, 165.xx, 170.xx, 171.xx,
172.xx, 173.xx, 174.xx, 175.xx, 176.xx, 179.xx, 180.xx,
181.xx, 182.xx, 183.xx, 184.xx, 185.xx, 186.xx, 187.xx,
188.xx, 189.xx, 190.xx, 191.xx, 192.xx, 193.xx, 194.xx,
195.xx, 196.xx, 197.xx, 199.xx, 199.xx, 200.xx, 201.xx,
202.xx, 203.xx, 204.xx, 205.xx, 206.xx, 207.xx, 208.xx,
230.xx, 231.xx, 232.xx, 233.xx, 234.xx, 235.xx, 236.xx,
237.xx, 238.xx, 239.xx
Gastrointestinal
Peptic ulcer 531.xx, 532.xx, 533.xx, 534.xx
Inflammatory bowel disease 555.xx, 556.xx
Diverticulitis 562.11 , 562.13
Chronic hepatitis 070.xx, 571.xx, 572.2, 572.3, 572.4, 572.8
Gallbladder disease &
Gallstones
574.xx, 575.xx, 576.xx
Musculoskeletal
Osteoarthritis 715.xx
Rheumatoid arthritis 714.xx
Gout 274.xx, 712.xx
Other arthritis 716.xx
Hip problems 719.05, 719.15, 719.25, 719.35, 719.45, 719.55, 719.65,
719.75, 719.95, 719.95, 726.5, 733.14, 733.15, 733.42, 820.xx
Low back pain 720.xx,721.3,721.42,722.10,722.52,722.73,722.83,722.93,
724.02,724.2,724.3, 724.4, 724.5, 724.6, 724.7, 724.8, 724.9
Pulmonary
Asthma 493
Chronic bronchitis 491
Emphysema 492
Chronic airway obstruction 496
Diabetes-related complexity
Macrovascular complications
Coronary artery disease 410, 410.0, 410.00, 410.01, 410.02, 410.1, 410.10,
410.11, 410.12, 410.2, 410.20, 410.21, 410.22, 410.3,
410.30, 410.31, 410.32, 410.4, 410.40, 410.41, 410.42,
410.5, 410.50, 410.51, 410.52, 410.6, 410.60, 410.61,
410.62, 410.7, 410.70, 410.71, 410.72, 410.8, 410.80,
410.81, 410.82, 410.9, 410.90, 410.91, 410.92, 411.0,
411.1, 411.8, 411.81, 411.89, 412, 413, 413.0, 413.1,
413.9, 414, 414.0, 414.00, 414.01, 414.02, 414.03,
414.04, 414.05, 414.1, 414.10, 414.11, 414.19, 414.8,
414.9
Congestive heart failure 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428, 428.0,
428.1, 428.9
Arrhythmia 423, 423.0, 423.1, 423.2, 423.8, 423.9, 427.31
Stroke 431, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01,
434.11, 434.91
(continued on next page)
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